Bristol Myers Sqibb News (NYSE:BMY)

10/28/201610:11AMBWBristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade
Award recognizes Bristol-Myers Squibb for driving innovation in immuno-oncology Bristol-Myers Squibb’s Immuno-Oncology franchise is three-time winner of Prix Galien USA awards Bristol-Myers Squibb Company (NYSE:BMY) announced today that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy... More...>>
10/27/20161:26PMDJNBristol-Myers Squibb Makes Moves to Reassure Investors
By Jonathan D. Rockoff and Tess Stynes Bristol-Myers Squibb Co. sought to convince investors Thursday that its future was bright despite a major cancer drug setback by unveiling an organizational revamp and $3 billion share buyback while reporting better-than-expected quarterly results. Shares in the New York-based drug... More...>>
10/27/20168:20AMDJNBristol-Myers Squibb Plans Organizational Revamp
Bristol-Myers Squibb Co. unveiled an organizational revamp that aims to more clearly focus its resources for growth as the drugmaker also reported better-than-expected third-quarter results and raised its 2016 outlook. In addition, the company authorized the repurchase of $3 billion of its shares and provided preliminary... More...>>
10/27/20168:09AMDJNBristol-Myers Squibb Plans Organizational Revamp, Unveils $3 Billion Share Buyback
By Tess Stynes Bristol-Myers Squibb Co. unveiled an organizational revamp that aims to more clearly focus its resources for growth as the drugmaker also reported better-than-expected third-quarter results and raised its 2016 outlook. In addition, the company authorized the repurchase of $3 billion of its shares and provided... More...>>
10/27/20166:59AMBWBristol-Myers Squibb Reports Third Quarter Financial Results
Increases Third Quarter Revenues 21% to $4.9 Billion Posts Third Quarter GAAP EPS of $0.72 and Non-GAAP EPS of $0.77 Achieves Key Regulatory Milestones for Opdivo Positive Advisory Opinion for the Treatment of Classical Hodgkin Lymphoma in Europe Application for Advanced Form of Bladder Cancer Accepted for Priority Review... More...>>
10/25/20168:00AMBWNew Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-T...
First presentation of Phase 2 CheckMate -205 cohort C data in classical Hodgkin lymphoma patients following treatment with autologous hematopoietic stem cell transplantation and brentuximab vedotin After a median follow-up of 8.8 months, Opdivo demonstrated an objective response rate as assessed by an independent radiologic... More...>>
10/24/20169:40PMDJNMerck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
Merck & Co.'s immunotherapy cancer drug Keytruda received U.S. Food and Drug Administration approval as a first-line treatment for certain lung cancer patients. The approval is for patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no EGFR or ALK genomic tumor aberrations... More...>>
10/24/20166:59AMBWBristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research
For third year in a row, BMS employees participated in a cycling relay to raise funds for Stand Up To Cancer’s efforts to accelerate cancer research Bristol-Myers Squibb’s (NYSE:BMY) Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer’s collaborative cancer research programs. In this... More...>>
10/21/20162:19PMBWU.S. Food & Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolu...
Submission based on results from Phase 2 study CheckMate -275 evaluating Opdivo in patients with previously treated platinum-refractory metastatic urothelial carcinoma Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application... More...>>
10/21/201611:03AMBWBristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public... More...>>
10/17/201612:15PMBWBristol-Myers Squibb Foundation Joins White House Cancer Moonshot
$25MM in funding will expand scope of community-based cancer treatment, care and support for underserved patients Today the Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care. In response to the Cancer Moonshot, the Foundation... More...>>
10/14/20166:59AMBWBristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed ...
First PD-1 inhibitor in a hematologic malignancy to receive positive CHMP opinion CHMP decision based on overall response rate demonstrated by data from two trials, CheckMate -205 and CheckMate -039 Bristol-Myers Squibb Company (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the... More...>>
10/09/20168:45AMBWOpdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small ...
Updated data from CheckMate -057 and -017 show Opdivo-treated patients had tripled the duration of response compared to those treated with docetaxel, with a minimum follow-up of two years In CheckMate -057, durable responses and complete responses were observed with Opdivo in both PD-L1 expressors and non-expressors Patient-reported... More...>>
10/09/20167:30AMBWUpdated Results Presented for the Opdivo (nivolumab) & Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma Fro...
Durable responses observed with the Opdivo and Yervoy combination in an updated analysis of CheckMate -016 Confirmed objective response rate for both combination regimen cohorts was 40.4% The safety profile of the Opdivo and Yervoy combination in metastatic renal cell carcinoma patients is consistent with previous reports... More...>>
10/09/20167:00AMBWSafety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
The combination of lirilumab and nivolumab in a Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy; Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab; Efficacy data will be presented at the Society for Immunotherapy of Cancer 2016 conference... More...>>
10/09/20162:44AMDJNStudy May Boost Use of Merck Lung-Cancer Drug
By Peter Loftus Patients with advanced lung cancer who took Merck & Co.'s immune-boosting drug Keytruda as their first treatment lived longer on average than those who received chemotherapy in a new study that could herald a big shift in treatment of the deadliest cancer. The finding could lead to wider use of... More...>>
10/09/20162:15AMBWBristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemother...
Bristol-Myers Squibb Company (NYSE:BMY) announced today the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 ≥1%. The study was powered to assess progression-free... More...>>
10/09/20162:15AMBWOpdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous ...
Opdivo-treated patients exhibited stable functioning and symptoms, whereas those treated with investigator’s choice of therapy exhibited statistically significant worsening of these outcomes Opdivo more than doubled the time to deterioration for most functional domains Bristol-Myers Squibb Company (NYSE: BMY) announced... More...>>
10/08/20163:09AMBWResults From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer
Confirmed overall response rate of 19.6% in all previously treated patients who received Opdivo Durable responses observed in PD-L1 expressors and non-expressors The safety profile of Opdivo in this study was consistent with previously reported studies Bristol-Myers Squibb Company (NYSE:BMY) announced today results from... More...>>
10/08/20162:15AMBWYervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study
Yervoy demonstrated a 28% reduction in the risk of death versus placebo in first disclosure of overall survival data from pivotal study CA184-029 (EORTC 18071) Risk of distant metastasis was reduced by 24% with Yervoy compared to placebo With longer follow-up, the recurrence-free survival benefit and safety profile remained... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20161028 19:40:08